A special livestream webinar for startup founders and investors.
Biotech Trends 2023
Hosted by Foley & Lardner, and 4thly. Biotech remains a red-hot area for startup founders and investors. Next-generation gene therapies, precision medicine, using AI and ML for speeding discovery and development of new drugs, and entire new delivery methods. What does the future look like, and how should investors and founders parse the opportunities in this sector? This panel of experts discussed these topics and more.

Panelists:

Marguerite Hutchinson
Marguerite was recently named as one of the Top 25 Women Leaders in Biotech by the Healthcare Technology Report. Most recently, she was CEO at a stealth, seed-stage UCSF spinout. Prior to that, she was Chief Business Officer at Frontier Medicines. As Chief Operating Officer & General Counsel at Plexxikon, her accomplishments included playing a pivotal role in the Phase 3 development plan for TURALIO®, approved in 2019 for the treatment of tenosynovial giant cell tumor (TGCT). She obtained her law degree from the University of San Diego and her bachelor’s degree from Harvard.

Louis Lehot
Louis Lehot is a partner and business lawyer with Foley & Lardner LLP, based in the firm’s Silicon Valley offices, where he is a member of the Private Equity & Venture Capital, M&A and Transactions Practices as well as the Technology, Health Care, Life Sciences and Energy Industry Teams. Louis focuses his practice on advising entrepreneurs and their management teams, investors and financial advisors at all stages of growth, from garage to global. Louis especially enjoys being able to help his clients achieve hyper-growth, go public and to successfully obtain optimal liquidity events. Learn more.

Kent Hawryluk
Kent Hawryluk is Co-founder & CEO of MBX Biosciences. Previously he was a co-founder and chief business officer of Avidity Biosciences (RNA), a publicly-traded genetic medicines company. Under his leadership, Avidity raised $130 million in equity financing and initiated a significant strategic partnership with Eli Lilly. Previously, he co-founded Marcadia Biotech and MB2. He serves as a partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund. He is a graduate of Princeton University, and holds an MSc from Indiana University-Purdue as well as an MBA from the Kellogg School of Management at Northwestern University.

Bret Waters, Moderator
Bret Waters has been in Silicon Valley his entire life as an entrepreneur, executive, and investor. Today he teaches entrepreneurship at Stanford University, runs the 4thly Startup Accelerator, and coaches startup CEO’s at Miller Center for Social Entrepreneurship. He’s successfully raised capital multiple times in his career, and the entrepreneurs he has worked with have raised hundreds of millions of dollars in capital. He received his MBA from the Kellogg School of Management at Northwestern University.